Spectrum of Fibrosing Diffuse Parenchymal Lung Disease

被引:27
作者
Morgenthau, Adam S. [1 ]
Padilla, Maria L. [1 ]
机构
[1] Mt Sinai Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA
来源
MOUNT SINAI JOURNAL OF MEDICINE | 2009年 / 76卷 / 01期
关键词
antisynthetase syndrome; dermatomyositis; diffuse parenchymal lung disease; Hermansky-Pudlak syndrome; hypersensitivity pneumonitis; idiopathic pulmonary fibrosis; nonspecific interstitial pneumonia; polymyositis; sarcoidosis; usual interstitial pneumonia; IDIOPATHIC PULMONARY-FIBROSIS; NONSPECIFIC INTERSTITIAL PNEUMONIA; HERMANSKY-PUDLAK-SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; NECROSIS-FACTOR-ALPHA; CONNECTIVE-TISSUE DISEASES; PLACEBO-CONTROLLED TRIAL; PIGEON-BREEDERS DISEASE; LOWER RESPIRATORY-TRACT; SURFACTANT PROTEIN-A;
D O I
10.1002/msj.20087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The interstitial lung diseases are a heterogeneous group of disorders characterized by inflammation and/or fibrosis of the pulmonary interstitium. In 2002, the American Thoracic Society and the European Respiratory Society revised the classification of interstitial lung diseases and introduced the term diffuse parenchymal lung disease. The idiopathic interstitial pneumonias are a subtype of diffuse parenchymal lung disease. The idiopathic interstitial pneumonias are subdivided into usual interstitial pneumonia (with its clinical counterpart idiopathic interstitial pneumonia), nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, desquamative interstitial pneumonia; respiratory bronchiolitis interstitial lung disease, and lymphocytic pneumonia. Sarcoidosis and hypersensitivity pneumonitis are the ? most common granulomatous diffuse parenchymal lung diseases. Rheumatoid arthritis, systemic sclerosis, and dermatomyositis/polymyositis (causing antisynthetase syndrome) are diffuse parenchymal lung diseases of known association because these conditions dire associated with connective tissue disease. Hermansky-Pudlak syndrome is a rare genetic diffuse parenchymal lung disease characterized by the clinical triad of pulmonary disease. oculocutaneous albinism, and bleeding diathesis. This review provides an overview of the chronic fibrosing diffuse parenchymal lung diseases. Its primary objective is to illuminate the clinical challenges encountered by clinicians who manage the diffuse parenchymal lung diseases regularly anti to offer potential solutions to those challenges. Treatment for the diffuse parenchymal lung diseases is limited, and for many patients with end-stage disease, lung transplantation remains the best option. Although much has been learned about the diffuse parenchymal lung diseases during the past decade, research in these diseases is urgently needed. Mt Sinai J Med 76:2-23, 2009. (C) 2009 Mount Sinai School of Medicine
引用
收藏
页码:2 / 23
页数:22
相关论文
共 179 条
  • [1] CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis
    Akira, M
    Hamada, H
    Sakatani, M
    Kobayashi, C
    Nishioka, M
    Yamamoto, S
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1997, 168 (01) : 79 - 83
  • [2] ALHAMEED FM, 2004, CAN RESPIR J, V17, P117
  • [3] PREDICTORS OF SURVIVAL IN SYSTEMIC-SCLEROSIS (SCLERODERMA)
    ALTMAN, RD
    MEDSGER, TA
    BLOCH, DA
    MICHEL, BA
    [J]. ARTHRITIS AND RHEUMATISM, 1991, 34 (04): : 403 - 413
  • [4] Ambrosini V, 2003, EUR RESPIR J, V22, P821, DOI 10.1183/09031936.03.00022703
  • [5] Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics
    Anderson, PD
    Huizing, M
    Claassen, DA
    White, J
    Gahl, WA
    [J]. HUMAN GENETICS, 2003, 113 (01) : 10 - 17
  • [6] Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico
    Anikster, Y
    Huizing, M
    White, J
    Shevchenko, YO
    Fitzpatrick, DL
    Touchman, JW
    Compton, JG
    Bale, SJ
    Swank, RT
    Gahl, WA
    Toro, JR
    [J]. NATURE GENETICS, 2001, 28 (04) : 376 - 380
  • [7] Pathogenetic pathways and novel pharmaco therapeutic targets in idiopathic pulmonary fibrosis
    Antomou, Katerma M.
    Pataka, Athanasia
    Bouros, Demosthenes
    Slafakas, Nikolaos M.
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (05) : 453 - 461
  • [8] Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus
    Arase, Y
    Ikeda, K
    Tsubota, A
    Saitoh, S
    Suzuki, Y
    Kobayashi, M
    Suzuki, F
    Someya, T
    Akuta, N
    Hosaka, T
    Kobayashi, M
    Kumada, H
    [J]. HEPATOLOGY RESEARCH, 2003, 27 (02) : 89 - 94
  • [9] ADVERSE IMPACT OF INTERSTITIAL PULMONARY FIBROSIS ON PROGNOSIS IN POLYMYOSITIS AND DERMATOMYOSITIS
    ARSURA, EL
    GREENBERG, AS
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1988, 18 (01) : 29 - 37
  • [10] Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis
    Ashitani, J
    Mukae, H
    Taniguchi, H
    Ihi, T
    Kadota, J
    Kohno, S
    Matsukura, S
    [J]. THORAX, 1999, 54 (11) : 1015 - 1020